Pfizer and Theraclone in $632 million antibody drug research deal
This article was originally published in Scrip
Executive Summary
The US discovery-stage biotech Theraclone Sciences has inked a multi-year R&D collaboration with Pfizer, with a potential $632 million in funding and milestones, in which the company will use its proprietary I-STAR discovery platform to help the pharma to identify monoclonal antibodies against up to four undisclosed targets in the areas of cancer and infectious disease.